Editor’s Note
Galderma’s launch of Sculptra® in India marks a significant step forward in regenerative aesthetics, backed by over 25 years of global clinical evidence. This introduction reflects the country’s shifting consumer focus toward skin health, minimally invasive treatments, and personalized care.
Galderma, the pure-play dermatology category leader, has announced the launch of Sculptra® in India, introducing the first proven regenerative biostimulator. Backed by more than 25 years of clinical evidence globally, the launch marks an important milestone in India’s rapidly evolving aesthetics landscape, where growing awareness around skin health, minimally invasive options and personalised solutions are redefining consumer expectations. Patients and healthcare professionals alike are looking to move beyond temporary correction towards regenerative solutions that work in harmony with the body’s own biological processes.
In addition to restoring volume, Sculptra also helps address collagen loss associated with the natural ageing process. As collagen production naturally decreases over time, the skin begins to lose its structural support, resulting in reduced firmness, volume loss and the appearance of wrinkles.
Globally, aesthetic medicine is witnessing a significant shift from correction to regeneration. Rather than seeking immediate or dramatic transformation, today’s consumers are increasingly looking for skin solutions that enhance skin quality, preserve natural features and deliver subtle, progressive results. This evolution has brought renewed focus on collagen, the skin’s structural foundation, and regenerative approaches that help restore what naturally diminishes with age.
With over 25 years of clinical evidence and extensive real-world experience, Sculptra has established itself as a trusted regenerative biostimulator among healthcare professionals across more than 40 countries and regions. Its unique mechanism of action helps stimulate collagen production across the skin’s structural framework, resulting in gradual improvements in facial volume, firmness and overall skin quality, with results that can last for more than two years.
The introduction of Sculptra further strengthens Galderma India’s Injectable Aesthetics portfolio and reflects the company’s continued commitment to bringing globally recognised innovations to Indian healthcare professionals. As the leader in pure-play dermatology, Galderma continues to advance science-backed solutions across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology, empowering healthcare professionals with innovative options while helping address the evolving needs of patients.
Sculptra is a regenerative biostimulator with a unique PLLA-SCA™ (poly-L-lactic acid) formulation. Designed to work with the body’s natural regenerative processes, Sculptra stimulates collagen production to gradually restore facial volume, improve skin quality and provide natural-looking, long-lasting results. With over 25 years of clinical evidence globally, Sculptra has become a trusted option for healthcare professionals seeking regenerative aesthetic solutions.
Sculptra® is an injectable medical device intended to be administered only by qualified and trained healthcare professionals. Individual suitability and outcomes may vary.